Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
Completed · Phase 4
Conditions studied: Percutaneous Coronary Intervention
In brief
The purpose of this study is to compare FFR measurements done with adenosine to FFR measurements done with contrast, where the contrast is injected using the ACIST CVi automated contrast injector. The ACCELERATION study will support a safer approach to FFR for patients by potentially reducing toxic drug exposure (adenosine). The 2 main objectives of the study are: 1. Perform a methods comparison between cFFR and the reference standard aFFR, where cFFR is performed using an automated injector with a standardized volume and rate of delivery of contrast with known osmolality. 2. Evaluate the association between final post-PCI FFR and long-term clinical outcomes. The long-term clinical outcomes will include TVR and composite MACE (death, MI, and TVR) at 30 days and 1 year.
Key facts
- Study ID
- NCT03557385
- Run by
- Duke University
- People needed
- 201
- Starts
- 2019-01-17
- Expected to finish
- 2023-04-04
- Last updated by the study team
- 2024-07-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Have the capacity to understand and sign an informed consent or have a legally authorized representative (LAR) that can understand and sign an informed consent prior to initial arteriotomy access
- Age > 18 years of age at the time of signing the informed consent
- Clinically stable and undergoing non-emergent cardiac catheterization for appropriate indications
- Willing to be contacted by telephone at 30 days (if no standard of care visit) and at 1 year with chart review for events.
- Target vessel with an intermediate lesion of 40-70% stenosis by angiographic assessment (a visual estimation by the operator). Serial lesions, diffuse disease, or ostial lesions ("all-comer" lesions) are acceptable if the operator would normally perform FFR and proceed with PCI (or other revascularization) if positive.
You may not qualify if…
- Any condition associated with a life expectancy of less than 1 year
- Participation in another clinical study using an investigational agent or device within the past 3 months
- Ejection fraction ≤ 35%
- Creatinine ≥ 2
- Severe valvular heart disease
- Decompensated acute diastolic or systolic heart failure
- Bronchospastic chronic obstructive pulmonary disease or other intolerance to adenosine
- ST-segment elevation myocardial infarction culprit lesion or lesions with any thrombus burden after diagnostic angiography
- Lesions with severe calcification after diagnostic angiography
- Lesions in a target vessel supplied by a patent graft
Where it is running
- Long Beach VA — Long Beach, California, United States
- Mercy Hospital — Coon Rapids, Minnesota, United States
- University of Minnesota — Minneapolis, Minnesota, United States
- Durham VA — Durham, North Carolina, United States
- Vanderbilt — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.